- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
APG4C Antibody (S166) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP1810e | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
APG4C Antibody (S166) Blocking Peptide - Product info | |
| Primary Accession | Q96DT6 |
| Clone Names | 70226138 |
| Calculated MW | 52497 Da |
APG4C Antibody (S166) Blocking Peptide - Additional info | |
| Gene ID 84938 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP1810e was selected from the S166 region of human APG4C. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
APG4C Antibody (S166) Blocking Peptide - Protein Information | |
| Name ATG4C | |
| Synonyms APG4C, AUTL1, AUTL3 | |
| Function Cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes | |
| Cellular Location Cytoplasm (Probable). | |
| Tissue Location Highly expressed in skeletal muscle, heart, liver and testis | |
APG4C Antibody (S166) Blocking Peptide - Related products
AP1810a: ATG4C Antibody (N-term)
AP1810b: ATG4C Antibody (Center)
AP1810c: ATG4C Antibody (C-term)
AP3364a: Phospho-ATG4C-S451 Antibody
AP3392a: Phospho-ATG4C-S177 Antibody
AP3440a: Phospho-ATG4C-S398 Antibody
AP3456a: Phospho-ATG4C-S166 Antibody
RI10456: ATG4C predesign siRNA
LY10583a: ATG4C Over-expression Lysate
BP1810a: APG4C Antibody (N-term) Blocking Peptide
BP1810b: APG4C Antibody (Center) Blocking Peptide
BP1810c: APG4C Antibody (C-term) Blocking Peptide
BP1810d: APG4C Antibody (S398) Blocking Peptide
BP1810e: APG4C Antibody (S166) Blocking Peptide
BP3364a: Phospho-APG4C-S451 Antibody Blocking Peptide
BP3392a: Phospho-APG4C-S177 Antibody Blocking Peptide
APG4C Antibody (S166) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
APG4 is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes.Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole).
REFERENCES
Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)